2010
DOI: 10.1016/j.ijrobp.2009.04.080
|View full text |Cite
|
Sign up to set email alerts
|

Quality of Life After Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
41
0
1

Year Published

2011
2011
2015
2015

Publication Types

Select...
5
4

Relationship

1
8

Authors

Journals

citations
Cited by 73 publications
(43 citation statements)
references
References 27 publications
(27 reference statements)
1
41
0
1
Order By: Relevance
“…Previous studies also indicated, by means of other scoring systems, that quality of life was not severely impaired by SABR [26], [27] and [28].…”
Section: Discussionmentioning
confidence: 79%
“…Previous studies also indicated, by means of other scoring systems, that quality of life was not severely impaired by SABR [26], [27] and [28].…”
Section: Discussionmentioning
confidence: 79%
“…In such a state an effective local therapy such as SBRT should, in theory, arrest the disease's progression and extend life. If a local therapy is associated with low toxicity, then life-extending treatment can be delivered without seriously impacting a patient's quality of life during or after treatment (12,22). The use of modern imaging to detect smaller lesions and the combined use with surgical and chemotherapeutic approaches makes SBRT a powerful tool to control disease progression in the oligometastatic state.…”
Section: Discussionmentioning
confidence: 99%
“…Those results are consistent with previous studies. [10][11][12] In a study comparing 202 SABR patients with a smaller cohort of patients treated with 3-dimensional conformal radiation therapy, Widder et al 11 found that global QoL and physical functioning were stable at any follow-up within the first year after SABR treatment. Lagerwaard et al 12 also reported no relevant deterioration over a 2-year period in both functioning and symptom scores in 382 patients referred for SABR from multiple Dutch centers.…”
Section: Discussionmentioning
confidence: 99%
“…Recent reports have assessed early QoL in patients with lung cancer treated with SABR and reported no clinically relevant deterioration in QoL scores. [10][11][12][13] Moreover, studies have reported only transient or subclinical declines in pulmonary function tests (PFTs), even in patients with severe pulmonary comorbidities. [14][15][16] Prospective studies addressing both QoL and pulmonary function are sparse and often limited by short follow-up periods.…”
Section: Introductionmentioning
confidence: 99%